Ipsen and EMS-Chemie Shine on the Stock Market, Vistry and Pearson Struggle
Several companies are experiencing positive or negative consequences following their presentations at the JP Morgan Healthcare Conference held in California. Other significant movements are generally driven by analysts' recommendations.
Orion
(+12%): The Finnish laboratory anticipates that its treatment Nubeqa could eventually generate more than 1 billion euros in annual revenue and expects strong growth in 2026, driven almost exclusively by this flagship product.
EMS-Chemie
(+7%): UBS upgrades its rating from neutral to buy, raising the price target from 670 CHF to 720 CHF.
Ipsen
(+6%): The FDA has granted its drug IPN60340 "breakthrough therapy" designation for first-line treatment of ineligible acute myeloid leukemia. "Ipsen has never really shared data on this project, as it is a recent initiative still in phase I/II development, but this announcement is positive and shows that Ipsen's partnership strategy not only enriches the pipeline but is also bearing fruit," notes Oddo BHF.
Abivax
(+4.4%): Stifel maintains a buy rating and raises its price target from 100 to 142 EUR.
Bayer
(+3%): The group announced a target margin of around 30% for its pharmaceutical division by 2030. The announcement was made at the JP Morgan Healthcare Conference in San Francisco.
Stocks on the Decline
Autoneum
(-11%): UBS downgrades its rating from buy to neutral and lowers the price target from 190 CHF to 175 CHF.
Vistry
(-8%): The British developer saw its deliveries and sales decline in 2025, leading to a drop in its forward sales portfolio at the start of 2026, amid ongoing caution from private buyers despite public housing support.
Fresenius Medical Care
(-6%): No clear explanation at this stage, although the group participated yesterday in the JP Morgan Healthcare Conference in San Francisco. Management expressed a certain caution for 2026, which will be a transitional year.
Pearson
(-5%): The publisher reported full-year 2025 financial results in line with forecasts but slightly revised its targets downward. The initially positive reaction was replaced by some skepticism, sending the share price lower.
Swissquote
(-4%): UBS maintains its sell recommendation and lowers the price target from 475 to 465 CHF.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (73.7%);
- neuroscience (20.6%);
- rare diseases (5.7%).
At the end of 2024, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (39.3%), North America (34.3%) and other (26.4%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
